ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Yong Xu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5129610687. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jihui Hao · 2 shared papers, 2015–2026 · strength 0.32
- Paper Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in adv… DOI 10.20892/j.issn.2095-3941.2025.0848 ↗
- Paper Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. DOI 10.1007/s12032-015-0513-2 ↗
Yi Liu · 1 shared paper, 2026 · strength 0.26
- Paper Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in adv… DOI 10.20892/j.issn.2095-3941.2025.0848 ↗
Tongguo Si · 1 shared paper, 2026 · strength 0.26
- Paper Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in adv… DOI 10.20892/j.issn.2095-3941.2025.0848 ↗
Chuntao Gao · 1 shared paper, 2026 · strength 0.26
- Paper Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in adv… DOI 10.20892/j.issn.2095-3941.2025.0848 ↗
Hao Wang · 1 shared paper, 2026 · strength 0.26
- Paper Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in adv… DOI 10.20892/j.issn.2095-3941.2025.0848 ↗
Hua Li · 2 shared papers, 2015–2019 · strength 0.16
- Paper Prognostic value of pre-treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association wi… DOI 10.3892/ol.2019.10809 ↗
- Paper Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. DOI 10.1007/s12032-015-0513-2 ↗
Yi Pan · 1 shared paper, 2019 · strength 0.11
- Paper Prognostic value of pre-treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association wi… DOI 10.3892/ol.2019.10809 ↗
Zhenguo Song · 1 shared paper, 2019 · strength 0.11
- Paper Prognostic value of pre-treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association wi… DOI 10.3892/ol.2019.10809 ↗
Chongbiao Huang · 1 shared paper, 2015 · strength 0.05
- Paper Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. DOI 10.1007/s12032-015-0513-2 ↗
Huan Zhang · 1 shared paper, 2015 · strength 0.05
- Paper Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. DOI 10.1007/s12032-015-0513-2 ↗
Tiansuo Zhao · 1 shared paper, 2015 · strength 0.05
- Paper Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. DOI 10.1007/s12032-015-0513-2 ↗
He Ren · 1 shared paper, 2015 · strength 0.05
- Paper Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. DOI 10.1007/s12032-015-0513-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.